GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

Abstract

Background Various parameters have been considered for predicting survival in pancreatic ductal adenocarcinoma. Information about western population is missing. The aim of this study is to assess the association between Glucose transporter type 1 (GLUT-1) expression and prognosis for patients with PDAC submitted for surgical resection in a European cohort. Methods Retrospective analysis of PDAC specimens after pancreatoduodenectomy assessing GLUT-1 expression according to intensity (weak vs strong) and extension (low if < 80% cells were stained, high if > 80%) was performed. Statistical analysis was performed using the exact Fisher test, Student t test or the Mann-Whitney U test. Survival was analysed using the Kaplan-Meier method and compared with the Log-rank test. The differences were considered significant at a two-sided p value of < 0.05. All statistical analyses were performed using SPSS® 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Results Our study consisted of 39 patients of which 58.9% presented with weak and 41.1% with strong intensity. The median extension was 90%: 28.2% cases presented with a low extension and 71.8% with a high extension. No significant differences related to intensity were found. The high-extension group showed a higher percentage of T3 PDAC (92.9% vs 63.6%, p = 0.042) and LNR20 (35.7% vs 0%, p = 0.037) as well as shorter disease-free survival (17.58 vs 54.46 months; p = 0.048). Conclusions Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.

High Expression of Solute Carrier Family 2 Member 1 (SLC2A1) in Cancer Cells Is an Independent Unfavorable Prognostic Factor in Pediatric Malignant Peripheral Nerve Sheath Tumor

“…Inhibition of HIF1A by chetomin decreases the expression of downstream gene-encoding of SLC2A1 in MPNST cell lines [ 25 ]. Corresponding to our study, high expression of SLC2A1 has been found to be associated with inferior outcomes in various malignancies in adults, including pancreatic cancer, colorectal cancer, breast cancer, lung cancer, and others [ 27 , 28 , 29 , 30 ]. Accordingly, pediatric cancers overexpressing SLC2A1, like adrenocortical carcinomas and liver vascular tumors, have worse prognosis than SLC2A1-negative tumors [ 31 , 32 ].…”

Comparing 2 crystal structures and 12 AlphaFold2-predicted human membrane glucose transporters and their water-soluble glutamine, threonine and tyrosine variants

“…et Medina Villaamil et al, 2011;Starska et al, 2015;Barron et al, 2016;Schlößer et al, 2017;White et al, 2018;Kuo et al, 2019;Heydarzadeh et al, 2020;Achalandabaso-Boira et al, 2020). Overexpression of GLUT2 is found in cancers of the breast, colon, liver, pancreas and small intestine (Tomita, 1999;Godoy et al, 2006;Hamann et al, 2018).…”

GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network

“…GLUT1 distributes widely in human body, its expression tends to be low in normal tissues or benign lesions compared with corresponding tumor tissues, which partially indicates a rapid development and poor prognosis 15 . Increasing evidences suggested that GLUT1 expression positively correlated with survival time and worse response to treatment 16 - 19 . But the mechanisms remain unclear in PAAD, especially the regulatory network of GLUT1 and competitive endogenous RNAs (ceRNAs), as well as the relationship between GLUT1 and malignant biological behaviors of PAAD.…”